- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Biologics and Biosimilars market will register a 4.7% CAGR in terms of revenue, the global market size will reach $ 269570 million by 2025, from $ 224600 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biologics and Biosimilars business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by type, application, key manufacturers and key regions and countries.
This study considers the Biologics and Biosimilars value and volume generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Merck
Amgen
Sanofi-Aventis
Johnson & Johnson
AbbVie
Eli Lilly
Pfizer
Novartis
Novo Nordisk
Innovent
Ganlee
Dong Bao
3sbio
Biotech
CP Guojian
Gelgen
Changchun High Tech
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Biologics and Biosimilars consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Biologics and Biosimilars market by identifying its various subsegments.
Focuses on the key global Biologics and Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biologics and Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Biologics and Biosimilars submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biologics and Biosimilars Consumption 2015-2025
2.1.2 Biologics and Biosimilars Consumption CAGR by Region
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Erythropoietin
2.2.4 Insulin
2.2.5 Vaccines
2.2.6 Other
2.3 Biologics and Biosimilars Consumption by Type
2.3.1 Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
2.3.2 Global Biologics and Biosimilars Revenue and Market Share by Type (2015-2020)
2.3.3 Global Biologics and Biosimilars Sale Price by Type (2015-2020)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Tumor
2.4.2 Diabetes
2.4.3 Cardiovascular
2.4.4 Hemophilia
2.4.5 Other
2.5 Biologics and Biosimilars Consumption by Application
2.5.1 Global Biologics and Biosimilars Consumption Market Share by Type (2015-2020)
2.5.2 Global Biologics and Biosimilars Value and Market Share by Type (2015-2020)
2.5.3 Global Biologics and Biosimilars Sale Price by Type (2015-2020)
3 Global Biologics and Biosimilars by Company
3.1 Global Biologics and Biosimilars Sales Market Share by Company
3.1.1 Global Biologics and Biosimilars Sales by Company (2018-2020)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Company (2018-2020)
3.2 Global Biologics and Biosimilars Revenue Market Share by Company
3.2.1 Global Biologics and Biosimilars Revenue by Company (2018-2020)
3.2.2 Global Biologics and Biosimilars Revenue Market Share by Company (2018-2020)
3.3 Global Biologics and Biosimilars Sale Price by Company
3.4 Global Biologics and Biosimilars Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Biologics and Biosimilars Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Biologics and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Biologics and Biosimilars by Regions
4.1 Biologics and Biosimilars by Regions
4.2 Americas Biologics and Biosimilars Consumption Growth
4.3 APAC Biologics and Biosimilars Consumption Growth
4.4 Europe Biologics and Biosimilars Consumption Growth
4.5 Middle East & Africa Biologics and Biosimilars Consumption Growth
5 Americas
5.1 Americas Biologics and Biosimilars Consumption by Countries
5.1.1 Americas Biologics and Biosimilars Consumption by Countries (2015-2020)
5.1.2 Americas Biologics and Biosimilars Value by Countries (2015-2020)
5.2 Americas Biologics and Biosimilars Consumption by Type
5.3 Americas Biologics and Biosimilars Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Biologics and Biosimilars Consumption by Regions
6.1.1 APAC Biologics and Biosimilars Consumption by Regions (2015-2020)
6.1.2 APAC Biologics and Biosimilars Value by Regions (2015-2020)
6.2 APAC Biologics and Biosimilars Consumption by Type
6.3 APAC Biologics and Biosimilars Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Biologics and Biosimilars by Countries
7.1.1 Europe Biologics and Biosimilars Consumption by Countries (2015-2020)
7.1.2 Europe Biologics and Biosimilars Value by Countries (2015-2020)
7.2 Europe Biologics and Biosimilars Consumption by Type
7.3 Europe Biologics and Biosimilars Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Biologics and Biosimilars by Countries
8.1.1 Middle East & Africa Biologics and Biosimilars Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Biologics and Biosimilars Value by Countries (2015-2020)
8.2 Middle East & Africa Biologics and Biosimilars Consumption by Type
8.3 Middle East & Africa Biologics and Biosimilars Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Biologics and Biosimilars Distributors
10.3 Biologics and Biosimilars Customer
11 Global Biologics and Biosimilars Market Forecast
11.1 Global Biologics and Biosimilars Consumption Forecast (2021-2025)
11.2 Global Biologics and Biosimilars Forecast by Regions
11.2.1 Global Biologics and Biosimilars Forecast by Regions (2021-2025)
11.2.2 Global Biologics and Biosimilars Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Biologics and Biosimilars Forecast by Type
11.8 Global Biologics and Biosimilars Forecast by Application
12 Key Players Analysis
12.1 Roche
12.1.1 Company Information
12.1.2 Biologics and Biosimilars Product Offered
12.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Roche Latest Developments
12.2 Merck
12.2.1 Company Information
12.2.2 Biologics and Biosimilars Product Offered
12.2.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Merck Latest Developments
12.3 Amgen
12.3.1 Company Information
12.3.2 Biologics and Biosimilars Product Offered
12.3.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Amgen Latest Developments
12.4 Sanofi-Aventis
12.4.1 Company Information
12.4.2 Biologics and Biosimilars Product Offered
12.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Sanofi-Aventis Latest Developments
12.5 Johnson & Johnson
12.5.1 Company Information
12.5.2 Biologics and Biosimilars Product Offered
12.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Johnson & Johnson Latest Developments
12.6 AbbVie
12.6.1 Company Information
12.6.2 Biologics and Biosimilars Product Offered
12.6.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 AbbVie Latest Developments
12.7 Eli Lilly
12.7.1 Company Information
12.7.2 Biologics and Biosimilars Product Offered
12.7.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Eli Lilly Latest Developments
12.8 Pfizer
12.8.1 Company Information
12.8.2 Biologics and Biosimilars Product Offered
12.8.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Pfizer Latest Developments
12.9 Novartis
12.9.1 Company Information
12.9.2 Biologics and Biosimilars Product Offered
12.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Novartis Latest Developments
12.10 Novo Nordisk
12.10.1 Company Information
12.10.2 Biologics and Biosimilars Product Offered
12.10.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Novo Nordisk Latest Developments
12.11 Innovent
12.11.1 Company Information
12.11.2 Biologics and Biosimilars Product Offered
12.11.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Innovent Latest Developments
12.12 Ganlee
12.12.1 Company Information
12.12.2 Biologics and Biosimilars Product Offered
12.12.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Ganlee Latest Developments
12.13 Dong Bao
12.13.1 Company Information
12.13.2 Biologics and Biosimilars Product Offered
12.13.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Dong Bao Latest Developments
12.14 3sbio
12.14.1 Company Information
12.14.2 Biologics and Biosimilars Product Offered
12.14.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 3sbio Latest Developments
12.15 Biotech
12.15.1 Company Information
12.15.2 Biologics and Biosimilars Product Offered
12.15.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.15.4 Main Business Overview
12.15.5 Biotech Latest Developments
12.16 CP Guojian
12.16.1 Company Information
12.16.2 Biologics and Biosimilars Product Offered
12.16.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.16.4 Main Business Overview
12.16.5 CP Guojian Latest Developments
12.17 Gelgen
12.17.1 Company Information
12.17.2 Biologics and Biosimilars Product Offered
12.17.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.17.4 Main Business Overview
12.17.5 Gelgen Latest Developments
12.18 Changchun High Tech
12.18.1 Company Information
12.18.2 Biologics and Biosimilars Product Offered
12.18.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.18.4 Main Business Overview
12.18.5 Changchun High Tech Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Biologics and Biosimilars Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Play
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
